Abstract
At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Current Drug Targets
Title: PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Volume: 8 Issue: 9
Author(s): Douglas E. Vaughan, Bart M. De Taeye and Mesut Eren
Affiliation:
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Abstract: At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Export Options
About this article
Cite this article as:
Vaughan E. Douglas, De Taeye M. Bart and Eren Mesut, PAI-1 Antagonists: Predictable Indications and Unconventional Applications, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662364
DOI https://dx.doi.org/10.2174/138945007781662364 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress in Essential Hypertension
Current Pharmaceutical Design Concurrent And Longitudinal Association Between Glycemic Control And Self Reported Medication Adherence Among Type 2 Diabetes Patients At A Tertiary Care Hospital In Malaysia
Current Diabetes Reviews Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Protein & Peptide Letters Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Misfolding of Apoprotein B-100, LDL Aggregation and 17-β -estradiol in Atherogenesis
Current Medicinal Chemistry The Effects and Underlying Mechanisms of Cell Therapy on Blood-Brain Barrier Integrity After Ischemic Stroke
Current Neuropharmacology Insulin Therapy for Improving Cardiac Surgical Outcomes
Current Drug Targets The Science of Hypoglycemia in Patients with Diabetes
Current Diabetes Reviews Cardiovascular Therapeutics Targets on the NO–sGC–cGMP Signaling Pathway: A Critical Overview
Current Drug Targets Valsartan Protects Against Contrast-Induced Acute Kidney Injury in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis
Current Vascular Pharmacology Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Access-site Complications of the Transradial Approach: Rare But Still There
Current Cardiology Reviews Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications
Current Diabetes Reviews